Tag: GW Pharmaceuticals

Debra BorchardtJanuary 13, 2020
epidiolex-medical-marijuana-1280x800-1280x800.jpg

3min00
GW Pharmaceuticals plc (GWPH) reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. The cannabis-based biotech firm said that it expects total net product sales to be approximately $108 million for the fourth quarter and approximately $309 million for the year ending December 31, 2019. The […]

William SumnerSeptember 25, 2019
daily_hit004-1280x533.png

4min00
It’s time for your Daily Hit of cannabis financial news for September 25, 2019. On the Site WeedMD WeedMD Inc. (TSX-V: WMD) (OTCQX: WDDMF) has closed its previously-announced bought-deal short-form prospectus offering of convertible debenture units at a price of $1,000 per Convertible Debenture Unit for aggregate gross proceeds of $13,115,000, which includes proceeds from the […]

William SumnerAugust 7, 2019
daily_hit004-1280x533.png

6min00
It’s time for your Daily Hit of cannabis financial news for August 7, 2019. On the Site LeafLink Online cannabis wholesale marketplace, LeafLink announced the completion of a $35M Series B round of funding. The round was led by Thrive Capital. Current investors Nosara Capital, Lerer Hippeau, Wisdom VC, and Thought Into Action Ventures also […]

StaffAugust 6, 2019
daily_hit004-1280x533.png

8min00
It’s time for your Daily Hit of cannabis financial news for August 6, 2019. On The Site GW Pharmaceuticals British biotech firm GW Pharmaceuticals pls (NASDAQ: GWPH) second-quarter net sales of $68.4 million of the company’s cannabis-related drug Epidiolex, which is prescribed for children with rare epilepsy diseases. For the first half of 2019, GW […]

StaffMay 8, 2018
daily_hit004-1280x533.png

6min00
It’s time for your Daily Hit on May 8, 2018 On The Site GW Pharmaceuticals GW Pharmaceuticals (NASDAQ: GWPH) reported mixed second-quarter results on Tuesday after the market close, as revenue came in ahead of consensus but earnings expectations missed the mark by a wide margin. U.K.-based GW Pharmaceuticals said it lost $3.12 a share on […]

Jack SmithMay 8, 2018
epidiolex-medical-marijuana-1280x800-1280x800.jpg

5min00
GW Pharmaceuticals (NASDAQ: GWPH) reported mixed second-quarter results on Tuesday after the market close, as revenue came in ahead of consensus but earnings expectations missed the mark by a wide margin. U.K.-based GW Pharmaceuticals said it lost $3.12 a share on $3.35 million in sales, though the company mentioned the positive outcome of the Epidioled […]

StaffApril 19, 2018
daily_hit004-1280x533.png

7min00
Here is your Daily Hit of cannabis news for April 19, 2018: On The Site: GW Pharmaceuticals Inc. GW Pharmaceuticals Inc. (GWPH) continues to get closer and closer to FDA approval of its drug Epidiolex for the rare forms of epilepsy Lennox-Gastaut and Dravet Syndrome. Epidiolex is GW’s lead cannabinoid product candidate and is a pharmaceutical formulation […]

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.